Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can only hope this is the start of many contracts Nd stock can get back up to atleast 5 dollars!
Breaking News - AcelRx Wins ~$3.5M US Army Medical Research Acquisition Contract For Dsuvia
5:33pm ET 7/16/2020 Benzinga
The United Stated Army Medical Research Acquisition Activity (USAMRAA), in support of the U.S. Army Medical Materiel Development Activity (USAMMDA), intends to negotiate solely (as prescribed in FAR 13.106(b)(1)(i)) with AcelRx Pharmaceuticals, Inc., 351 Galveston Drive, Redwood City, CA, 94063-4736, as the only responsible source that can provide one (1) commercial lot of 3,200 boxes of U.S. Food and Drug Administration (FDA) approved Sufentanil NanoTab brand name Dsuvia (New Drug Application (NDA)) # 209128 letter dated 12 December 2016. Dsuvia is for the management of acute pain in adults in medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments. Dsuvia is supplied in a 30 microgram tablet in a single-dose, prefilled applicator for administration by a healthcare professional, and it will not be available in retail pharmacies or for outpatient use. This acquisition is being conducted under FAR Part 12 Acquisition of Commercial Items. Provisions and clauses in effect through Federal Acquisition Circular (FAC) 2020-04, dated 15 January 2020, are incorporated.
USAMMDA, located in Fort Detrick, MD, is a subordinate activity under U.S. Army Medical Research and Development Command (USAMRDC) supporting the Command as the primary advanced development medical research, development, and acquisition organization within DOD and is responsible for meeting medical developmental requirements from both the Army and other military services. The USAMMDA is the Department of Defense's (DOD) medical product development activity for products designed to protect and preserve the lives of Warfighters. The USAMMDA develops new drugs, vaccines, devices, and medical support equipment that enhance readiness, ensures the provision of the highest quality medical care to the DOD, and maximizes survival of medical casualties on the battlefield. USAMMDA project managers guide the development of medical products for the U.S. Army Medical Department, other U.S. Services, the Joint Staff, the Defense Health Agency, and U.S. Special Forces community. The process takes promising technology from DOD, industry, and academia to U.S. Forces, from the testing required for FDA approval or licensing, to fielding and sustainment of the finished product.
USAMMDA’s, Warfighter Protection and Acute Care (WPAC) Project Management Office intends to procure firm-fixed-price contract for FDA approved brand name Dsuvia to be used to conduct a comparative clinical trial to aid clinical practice guideline development. USAMMDA has a requirement for one commercial lot of 3,200 boxes of FDA approved brand name Dsuvia, with a base and three (3) optional Contract Line Item Numbers (CLINs) to procure up to 3,000 boxes per CLIN of FDA brand name Dsuvia. The goal of the clinical trial is gain information regarding acceptability of Dsuvia compared to Oral Transmucosal Fentanyl Citrate (OTFC) in an Emergency Room (ER) setting in patients with moderate to severe pain requiring an opioid. The clinical trial contains several secondary endpoints including healthcare provider feedback. Based on the above information, the only technically acceptable product is provided by AcelRx Pharmaceuticals, Inc. The maximum estimated dollar amount for the duration of the contract is $3,525,800.00.
The intended procurement will be classified under North American Industry Classification System (NAICS) 325412 Pharmaceutical Preparation Manufacturing with a Small Business Size Standard of 1250 employees. This notice of intent is not a request for competitive proposals and no solicitation document will be posted for this requirement. However, parties interested in responding to this notice shall submit technical data, including cost, sufficient to determine capability in providing the same product. All capability statements received by closing of this notification of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
Who cares what this board says or doesn't say? LOL -it hasn't been a place of information on this stock for a long time. You place too much emphasis on Ihub if you are disappointed in a forum not reacting to a stock.
This is the most pathetic message board of all time. MLNT goes private, screws their shareholders and now screwing ACRX shareholders and nobody comments
https://www.businesswire.com/news/home/20200527005568/en/Tetraphase-Announces-Amendment-Merger-Agreement-AcelRx-Pharmaceuticals/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT
https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-revised-merger-agreement-with-tetraphase-301067693.html
TTPH
ACRX
I've been long in this stock for a while. It's in my IRA and also my margin account. They are building quite a company. 2-3 more years and I look forward to where we will be here.
they are attempting to steal ttph
good news?
Zacks Investment Research, Inc. upgrades ACELRX PHARMACEUTICALS INC from NEUTRAL to OUTPERFORM.
BY Investars Analyst Actions - private
— 3:10 PM ET 05/09/2020
On May 9, 2020 Zacks Investment Research, Inc. upgraded ACELRX PHARMACEUTICALS INC ( ACRX
Loading...
Loading...
) from NEUTRAL to OUTPERFORM.
This board is dead in the water. Quarterly report was mostly positive. Earnings missed by 3 cents but was not deadly with what is going on currently. Sales were positive. Projects were very positive, Analysts were very positive. With military sales coming on 4th quarter and possibly some in third quarter things are really looking up. I didn't expect this much good news. I'm happy.
I’m with you on that my friend. I’ve been following ACRX for the past couple months. It’s a very smooth and steady upward climb. I’m very happy with their progress. I hope the merger goes through with TTPH.
Then I’m in for the long haul...
I believe they are very well managed, which is why I’m holding out for the long term. Good luck to all...
After doing major Due Diligence on this company I am convinced that with the purchase of TTPH, ACRX could be a real sleeper. With that in mind I became a shareholder yesterday. I hold long therefore I do not expect things to happen immediately.
Several promising known drugs stand out as potential inhibitors of SARS-Cov-2 main protease, including Carfilzomib, Eravacycline, Valrubicin, Lopinavir and Elbasvir. Carfilzomib, an approved anti-cancer drug acting as a proteasome inhibitor, has the best MM-PBSA-WSAS binding free energy, -13.8 kcal/mol. The second-best repurposing drug candidate, eravacycline, is synthetic halogenated tetracycline class antibiotic.
https://pubs.acs.org/doi/10.1021/acs.jcim.0c00179
I found this helpful information and wanted to share. Sorry I couldn't share the chart as it made it easier to read. But this good enough.
Acelrx Pharmaceutica (ACRX) Analyst Forecast
Next 12 months ?
Current Price
$1.27
52-week High
$4.00
52-week Low
$0.70
MEAN
$7.00
+451.18%
HIGH
$9.00
+608.66%
LOW
$4.00
+214.96%
Last Price
$1.27
Previous Close
$1.32
Change
$-0.05
Open
$1.30
Volume
1,065,216
Avg. Volume (100-day)
1,039,255
Market Capitalization
$102.12M
Days Range
$1.12 - $1.32
52-week Range
$0.70 - $4.00
Dividend Yield
—
Ex. Dividend Date
—
Nice if you loaded under $1- took some profits here last night. Post-May should see a very nice recovery as we see opi off the radar as evil medicine and increase in DoD $.
Aquisitions should be a good sign for longs. If they can afford to buy another company, even with stocks, they are planning something...will start adding here.
AcelRx Pharmaceuticals (NASDAQ:ACRX) has agreed to acquire Tetraphase Pharmaceuticals (NASDAQ:TTPH) in an all-stock transaction valued at ~$14.4M. Specifically, TTPH stockholders will receive 0.6303 of an ACRX share for each TTPH share owned.
Ok thanks. I've had this a long time
No catalyst right now in this market. I am just bottom stock searching. This has been on the radar for over a year now. Best to you.
What's the catalyst?
On radar. Hoping for a nice move soon. Best to all here.
Ah of course! I had forgotten that.
Just posted: fourth quarter earnings will be announced before market on Monday March 16 according to AcelRX website
The DOD funded the development of the products.Need for field administered pain treatment when IV was not available or feasible.
I must be missing something. Why would the DOD buy?
If DOD starts buying, could see some nice movement here.
looks like they are done selling.
lets see if they throw a bone at this levels.
going lower, lower, lower
closing price 2-14-20 $1.60
looks like everyone gave up on this pig, including the management. I guess they took our money and ran.
Thanks, I'll check it out!
Stocktwits has a decent chat, not a whole lot of clowns there compared to the usual. I use it occasionally for news. I loaded at 1.77 - then 2.06 hope it gets past resistance at 2.50 to 4!
* * $ACRX Video Chart 12-11-19 * *
Link to Video - click here to watch the technical chart video
Ha! I was wondering that not two hours ago! Where is everyone? This is fantastic. Plus, look at all that insider buying!
Straight fire! Where the hell is the active chat room for this stock??
We have a real bang up management team here. I bet their paychecks have not gone down with shareholder value
Shorting it that’s what they do
strange that one analyst would drop the target to $2 from $7 and the average target is over $7. Does someone know something or are the analysts just making up random numbers.
* * $ACRX Video Chart 11-11-19 * *
Link to Video - click here to watch the technical chart video
WTF is wrong with these idiots that they can't sell their FDA Approved product -- under $2 again? These morons will be put out of biz if they don't FINALLY show some improved #s in earnings. Talentless morons run this company
$ACRX amended its supply agreement with SpecGX LLC to extend the term through December 31, 2022 https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13662267
Really moving today. Up over 10% and so glad I added the last few weeks.
Yeah me too. These are so cheap.
Nice news...military health symposium. A lead into that military contract? Would be nice.
I disagree. Management laid out their plan for the commercial launch of Dsuvia right after FDA approval. They are on schedule and in many cases ahead of the commercial launch outline they set forth during the investor day they held last December. Anyone doubting ACRX management team’s desire to create long term shareholder value has not followed the company for very long.
https://finance.yahoo.com/amphtml/news/acelrx-pharmaceuticals-inc-acrx-q2-012402390.html
It's still a very small company and isn't looking for a buyout. The recent lawsuit against the top 3 companies didn't help, in addition to the red sea we have. I'm not concerned at all, when it becomes profitable and hospitals have to start using something other than traditional based op's this thing will really move.
we have a solid drop in this stock. fda approval, good product and management that shows no sign of success. obviously shareholder value is not one of their priorities
In a sea of red, which thankfully there are things such as Puts...this is still doing okay. I was okay with ER and outlook. Cheap shares for long hold. Added 15% to my long position today.
Followers
|
95
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1442
|
Created
|
02/13/11
|
Type
|
Free
|
Moderators |
Market Cap: $108 Million
Cash: $72 Million
Price: $2.40
Shares Out: 45.3 Million
Upcoming Major Milestones
Zalviso Phase 3 Results in July 2017
DSUVIA PDUFA Date October 12, 2017
Zalsviso NDA Resubmission in Q4 2017
DSUVIA CHMP Opinion in 1H 2018 (EU Approval )
Presentation June 2017
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjczNjExfENoaWxkSUQ9MzgxNTY1fFR5cGU9MQ==&t=1
Jefferies Sees Strong Upside in AcelRx Pharmaceuticals’ Shares and Set a $7 Price Target
https://finance.yahoo.com/news/jefferies-sees-strong-upside-acelrx-145225845.html
Biotech Catalyst Play: AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)...
https://insiderfinancial.com/biotech-catalyst-play-acelrx-pharmaceuticals-inc-nasdaqacrx
While Zalviso is our near-term catalyst, the DSUVIA decision probably holds more weight from a valuation perspective. Why? Because peak sales for this one are estimated at a little over $1.1 billion in the US alone. If FDA gives a green light for commercialization to the asset, therefore, the company could have a blockbuster drug on its hands. Combine that with the close to $400 million in revenues potential from Zalviso, and AcelRx could very justifiably become a multibillion-dollar biotech company before the end of the decade.
https://finviz.com/quote.ashx?t=acrx&ty=c&ta=1&p=d
Shs Outstand | 119.10M |
Shs Float | 116.83M |
Short Float | 13.47% |
Insider Own | 2.00% |
Inst Own | 34.80% |
Inst Trans | 43.60% |
Inst Trans | 43.60% |
ROE | 66.50% |
ROI | 120.80% |
Employees | 54 |
Forward P/E | 16.13 |
Recom | 1.70 |
52W Range | 1.01 - 2.94 |
minor resistance $1.70 [-chart]finviz.com/chart.ashx?t=acrx&ty=c&ta=1&p=d&s=l[/chart]
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |